CNSY
Cerenome, Inc.
There isn't enough reported data to score CNSY yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CNSY Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
CNSY's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CNSY PE Valuation
CNSY has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CNSY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CNSY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CNSY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$69.50 | +$51.75 |
| Q4 2024 | -$58.50 | +$96.50 |
| Q3 2024 | -$108.50 | +$40.00 |
| Q2 2024 | -$124.25 | +$70.50 |
| Q1 2024 | -$121.25 | +$148.75 |
| Q4 2023 | -$155.00 | +$133.75 |
| Q3 2023 | -$148.50 | +$177.75 |
| Q2 2023 | -$194.75 | +$165.25 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 157% for CNSY versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
CNSY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $411K | -70% |
| Q1 2026 | $1M | -2.9% |
LLY has the edge over CNSY in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2204% | -2093 points |
| Q1 2026 | -693% | -359 points |
| Q4 2025 | -420% | N/A |
| Q3 2025 | -321% | N/A |
| Q2 2025 | -111% | N/A |
| Q1 2025 | -334% | N/A |
CNSY's operating margin was −2204% last quarter, down 2093 points from the same quarter a year ago, near the bottom of its range since 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CNSY in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CNSY on profitability, with a higher operating margin.
CNSY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | -$1.8M |
| Q1 2026 | -$7.1M | -$881K |
| Q4 2025 | -$6.3M | -$5.1M |
| Q3 2025 | -$2.6M | +$1.1M |
| Q2 2025 | -$5.8M | -$4.6M |
| Q1 2025 | -$6.2M | -$1.6M |
| Q4 2024 | -$1.2M | +$659K |
| Q3 2024 | -$3.7M | -$1.3M |
CNSY has burned cash in almost every quarter: −$24M over the past year, against −$17M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CNSY on cash generation, producing positive trailing cash flow while its opponent burns cash.
CNSY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +89% | +275K shares |
| 1 year | +237% | +410K shares |
| 3 years | +1834% | +553K shares |
CNSY has 582,669 diluted shares, up 237% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $374,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CNSY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CNSY Net Leverage
CNSY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CNSY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.2 | Oversold |
| Stochastic | 6.0 | Oversold |
CNSY's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CNSY PE vs Healthcare Sector
CNSY has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CNSY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.50 | 49% below |
| 20 week MA | $2.61 | 70% below |
| 50 week MA | $5.70 | 86% below |
| 100 week MA | $11.8 | 93% below |
| 200 week MA | $35.8 | 98% below |
CNSY is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CNSY on trend strength, trading above more of its moving averages.
CNSY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $922.5 | $836.3 | -9.3% |
| 2021 | $836.3 | $442.5 | -47% |
| 2022 | $442.5 | $116.3 | -74% |
| 2023 | $116.3 | $43.8 | -62% |
| 2024 | $43.8 | $29.0 | -34% |
| 2025 | $29.0 | $14.5 | -50% |
| 2026 YTD | $14.5 | $0.77 | -95% |
CNSY has finished every year since 2020 lower, and it's down 95% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CNSY on returns for 2026, with the stronger performance.